Vernalis PLC: Announcement of Results for Year Ended 31 Dec 2013

Vernalis PLC: Announcement of Results for Year Ended 31 Dec 2013  WINNERSH, UNITED KINGDOM -- (Marketwired) -- 04/01/14 --   1 April 2014  LSE: VER  Announcement of Results for the year ended 31 December 2013  Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2013.  Financial Highlights      --  Financial performance ahead of market expectations           --  Revenue was GBP14.1 million (2012: GBP14.6 million)     -Frovatriptan royalty income was up 16 % at GBP6.7 million (2012:  GBP5.7 million) primarily due to a 14% increase in volume of activepharmaceutical ingredient (API) supplied, with underlying in-market sales made by Menarini flat  - Research collaboration income was GBP7.1 million (2012: GBP8.7 million) including GBP2.5 million of milestones payments (2012: GBP2.6 million) allowing our research organisation to remain self-funding      --  Operating costs before exceptional items were GBP19.3 million (2012:     GBP18.2 million), up 6% due to preparatory activities for expansion     into the US and investment in the NCE pipeline (V158866 and V81444)           --  Pre-exceptional loss for the year was GBP5.6 million (2012: GBP5.2     million) and GBP4.0 million (2012: GBP5.2 million) on a          post-exceptional basis           --  Cash resources including cash and cash equivalents and held to     maturity assets reduced by GBP4.7 million in the year following:     -GBP2.0 million proof-of-concept milestone payment to Tris for CCP-01 and  - GBP0.9 million foreign exchange loss on the conversion of cash held in US dollars into sterling      --  Balance sheet remains strong with GBP76.9 million of cash resources     and no debt     Operational Highlights  Cough Cold Commercial Pipeline:      --  CCP-01 proof-of-concept achieved and milestone paid to Tris (March     2013)           --  Successfully completed single and multi-dose pivotal bioavailability     studies (November 2013 and February 2014), completing      the clinical     studies required for NDA filing           --  Positive interim six months stability data for CCP-01 has been     generated and NDA filing on track for mid-2014           --  Four further programmes in active development at Tris, and we aim to     achieve POC on all four of the remaining programmes during 2014     Frovatriptan (marketed) (Migraine):      --  Underlying Menarini sales flat at EUR26.4 million (2012: EUR26.5     million)           --  Menarini outlook for 2014 is for flat underlying sales vs 2013, both     in tablet volumes and sales revenue           --  We expect Menarini to reduce stock in 2014 with 2 shipments of API,     one in each half of the year     NCE Development Pipeline:  V81444 (CNS diseases)      --  Phase Ib/II POC study initiated (July 2013) with data anticipated in     H1 2014     V158866 (Pain)      --  Phase II POC study initiated (April 2013) and progressing well. Of a     total of 36 subjects, 16 have completed and a further 4 are enrolled.     Data now anticipated around the end of 2014     AUY922 (Cancer)      --  Phase I and Phase II studies in multiple oncology indications     including lung and breast continue with Novartis     Tosedostat - CHR2797 (Cancer)      --  Cell Therapeutics reported positive interim results from an     investigator-initiated Phase II trial at the 55th American Society of     Haematology annual meeting (December 2013)           --  The partial clinical hold on investigator led trials was removed by     FDA in January 2014 enabling studies to resume     RPL554      --  Anti-inflammatory study results announced by Verona Pharma (March     2013)           --  Verona announced a successful GBP14 million fundraising in March 2014.     Some of the proceeds are intended to be used to develop RPL554 in     three clinical studies using a nebulised formulation in patients with     severe COPD and additional studies are planned to prepare for a larger     Phase IIb study in hospitalised COPD patients. Results are expected     in     2015     Research Collaborations:      --  New collaboration with AKP announced (October 2013) and GBP0.3 million     milestone earned (March 2014)           --  First Servier collaboration extended for a further 2 years (March     2013)           --  GBP2.5 million of milestones earned from successful collaboration with     Genentech (February and March 2013)     Expected 2014 Newsflow:      --  V81444 (CNS diseases) - Complete Phase Ib/II POC study (Data H1 2014)           --  CCP-01 - Filing of NDA (Mid 2014)           --  Proofs-of-concept on all four remaining programmes in cough cold     pipeline (by 2014 year end)           --  V158866 (Pain) - Complete Phase II POC study (Data around 2014 year     end)           --  AUY922 (Cancer) - Multiple Phase I and II study results (Novartis)     (undisclosed)           --  Tosedostat - CHR2797 (Cancer)- Phase II study results (Chroma)     (undisclosed)           --  Achieve milestones under existing collaborations (undisclosed)           --  Secure new research collaborations (undisclosed)     Ian Garland, Chief Executive Officer, commented, "We made significant progress across all three elements of our strategy during 2013 and continued our strong financial and operational performance. Our lead cough cold programme, CCP-01, progressed rapidly achieving proof-of-concept, successfully completing both required pivotal clinical studies and achieving six month accelerated stability. We are on target therefore for an NDA filing in mid-2014. With four further cough cold programmes in development we aim to achieve POC on all four of these programmes in the coming year.   In the NCE pipeline we initiated two POC studies for V81444 and V158866 and expect data from both, during 2014. We also had another positive year in our research business following on from last year's record performance and continue to be self-funding.   The outlook for 2014 and beyond is extremely positive as we get closer to our first NDA filing from the cough cold portfolio and its potential approval in the first half of 2015."  Presentation & Conference Call  Vernalis management will host a presentation at 9.00am (UK) at  Brunswick's offices, 16 Lincoln's Inn Fields, London WC2A 3ED today. It  will also be available via webcast at http://www.vernalis.com/  investor-centre/presentations-and-webcasts and www.cantos.com and via  conference call, which can be joined by dialling: +44 (0) 20 3139 4830,  Passcode #35707904.  Enquiries:  Vernalis plc:  Ian Garland, Chief Executive Officer   +44 (0) 118 938 0015  David Mackney, Chief Financial Officer  Canaccord Genuity Limited (Nominated Adviser):   +44 (0) 20 7523 8350  Lucy Tilley  Dr Julian Feneley  Henry Fitzgerald-O'Connor  Shore Capital (Joint Broker)   +44 (0)20 7408 4090  Bidhi Bhoma  Toby Gibbs  Brunswick Group:   +44 (0) 20 7404 5959  Jon Coles  Click on, or paste the following link into your web browser, to view  the associated PDF document.  http://www.rns-pdf.londonstockexchange.com/rns/6618D_1-2014-3-31.pdf  This information is provided by RNS  The company news service from the London Stock Exchange  END   Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com